Argentum Pharmaceuticals Wins Patent Invalidation Trial against the Sole Remaining Patent Protecting Janssen’s ZYTIGA®

January 17, 2018

Responsive image

NEW YORK, Jan. 17, 2018 /PRNewswire/ — Today, the U.S. Patent & Trademark Office (PTO) issued a final written decision in Argentum Pharmaceuticals LLC’s inter partes review (IPR) against the sole unexpired patent listed as covering Janssen Oncology, Inc.’s ZYTIGA® (abiraterone…

Category: Precious Metals